Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH

Recruiting now

Conditions studied: Metabolic Dysfunction-Associated Steatotic Liver Disease, Hepatocellular Carcinoma, Metabolic Dysfunction-Associated Steatohepatitis, Liver Transplant

In brief

The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH), whether newly diagnosed or previously identified at the center during follow-up or as part of routine diagnostic and therapeutic care. The aim of the study is to identify predictive factors related to the prognosis of patients with metabolic liver disease (MASLD/MASH). Specifically, the study seeks to uncover biomarkers that can identify individuals at risk of requiring a liver transplant or developing HCC.

Key facts

Study ID

NCT06813508

Run by

IRCCS Azienda Ospedaliero-Universitaria di Bologna

People needed

1000

Starts

2024-11-20

Expected to finish

2044-11-20

Last updated by the study team

2025-02-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients with a diagnosis of MASLD, established according to the most recent published guidelines (EASL, EASD, EASO)
• Age ≥18 years
• Inclusion Criteria for Biological Sample Collection:
• Patients requiring liver biopsy for diagnostic purposes, as indicated by the most recent published guidelines (EASL, EASD, EASO)

You may not qualify if…

• No exclusion criteria.

Where it is running

• IRCCS Azienda Ospedaliero-Universitaria di Bologna — Bologna, Bologna, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.